Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study.

The immune impairment related to some haematological malignancies and their treatments is considered responsible for the more severe COVID-19 [[1]] and the lower response rate to anti-SARS-CoV-2 vaccines in these patients [[2], [4]]. A total of 481 serological tests (Supplementary Figure 1) were performed over 9 months on 312 CML patients and we found 35 patients (11.2%) to be seropositive, of whom 23 (65.7%) recalled COVID-19 symptoms in the previous months and 12 (34.3%) were asymptomatic. Anti-SARS-CoV-2 seroprevalence, COVID-19 symptoms and persistence of natural anti-RBD antibodies in CML patients. [Extracted from the article]